Drug Trial Radar · NCT03735979
Multi-arm Optimization of Stroke Thrombolysis
Last checked: Nov 20, 2026Latest source record: Feb 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
514
Actual
Start
Oct 15, 2019
Primary completion
Dec 1, 2023
Study completion Oct 31, 2024
Sponsor
- Lead sponsor
- Washington University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Neurological Disorders and Stroke (NINDS)
- First posted
- Nov 8, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary efficacy objective of the MOST trial is to determine if argatroban (100µg/kg bolus followed by 3µg/kg per minute for 12 hours) or eptifibatide (135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours) results in improved 90-day modified Rankin scores (mRS) as compared with placebo in acute ischemic stroke (AIS) patients treated with standard of care thrombolysis (0.9mg/kg IV rt-PA or 0.25mg/kg IV tenecteplase or TNK) within three hours of symptom onset. Patients may also receive endovascular thrombectomy (ET) per usual care. Time of onset is defined as the last time the patient was last known to be well.
Conditions
- Acute Ischemic Stroke
Interventions
ArgatrobanDrug
Direct Thrombin Inhibitor - Argatroban is a derivative of arginine that competitively binds to the active site of thrombin thereby preventing fibrin deposition. With a half-life of 30 minutes, argatroban has an immediate anticoagulant effect after IV administration which is rapidly reversed with discontinuation of the drug.
EptifibatideDrug
GP 2b/3a Receptor Inhibitor - The final step of platelet aggregation is mediated via the GP2b/3a receptor. Eptifibatide was specifically developed to ensure rapid inhibition of platelet aggregation (within 15 minutes), a short half-life (\~2 hours) and rapid dissociation from platelets with 50% restoration of platelet function within 2-4 hours of discontinuation.
PlaceboDrug
IV placebo solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- 90-day Utility Weighted Modified Rankin Scores (UW-mRS)Time frame: 90 days after randomization
Locations
61 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama Hospital
Birmingham, Alabama
St. Jude Medical Center
Fullerton, California
UCSD Health La Jolla
La Jolla, California
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
UC Irvine Medical Center
Orange, California
UCSD Medical Center - Hillcrest Hospital
San Diego, California
San Francisco General Hospital
San Francisco, California
UCSF Medical Center
San Francisco, California
Santa Barbara Cottage Hospital
Santa Barbara, California
Yale New Haven Hospital
New Haven, Connecticut
Baptist Medical Center Jacksonville
Jacksonville, Florida
Mayo Clinic Hospital
Jacksonville, Florida
Jackson Memorial Hospital
Miami, Florida
Sarasota Memorial Hospital
Sarasota, Florida
Tampa General Hospital
Tampa, Florida
Grady Memorial Hospital
Atlanta, Georgia
University of Chicago Medical Center
Chicago, Illinois
Loyola University Medical Center
Maywood, Illinois
Javon Bea Hospital - Riverside
Rockford, Illinois
Central DuPage Hospital
Winfield, Illinois
University of Kansas Hospital
Kansas City, Kansas
University of Kentucky Hospital
Lexington, Kentucky
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
UMASS Memorial Medical Center
Worcester, Massachusetts
University of Michigan University Hospital
Ann Arbor, Michigan
Henry Ford Hospital
Detroit, Michigan
McLaren Flint
Flint, Michigan
Trinity Health Saint Mary's
Grand Rapids, Michigan
Fairview Southdale Hospital
Edina, Minnesota
University of Minnesota Medical Center Hospital
Minneapolis, Minnesota
Regions Hospital
Saint Paul, Minnesota
Saint Luke's Hospital
Kansas City, Missouri
St. Louis University Hospital
St Louis, Missouri
Barnes Jewish Hospital
St Louis, Missouri
University of New Mexico Hospital
Albuquerque, New Mexico
North Shore University Hospital
Manhasset, New York
Mount Sinai Beth Israel
New York, New York
SUNY Upstate University Hospital
Syracuse, New York
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.